Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sorafenib for recurrent or progressive adamantinomatous craniopharyngioma
ChiCTR2400094147Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in craniopharyngioma (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
sorafenib
03
Conditions
craniopharyngioma
Beyond the preview
Go deeper on ChiCTR2400094147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094147.